Drug Delivery to the Lungs (DDL) is recognised as one of the major European conferences in respiratory drug delivery and a key international meeting for the rest of the world. It's mission is to provide a vehicle for the advancement of respiratory science and to share recent developments in inhalation therapy in a friendly and informal environment. Since the first meeting, DDL has also grown in stature and importance to cover all aspects of respiratory delivery from early research through pharmacology, pre-clinical, chemistry manufacturing and controls (CMC), regulatory as well as industrialisation and commercialisation. The conference attracts a range of attendees from scientists, academics, clinicians, regulators and industrial experts specialising in all aspects of developing medicines for inhalation. DDL is a not-for-profit conference and any surpluses are reinvested into research and training of the next generation of aerosol and drug delivery scientists. DDL also aims to be affordable for students and academic researchers as well as scientists from all levels of industry. This gives everyone the opportunity to publish and present their work, visit exhibitors’ stands and hold discussions with a wide variety of experts in the field.